SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved GOMEKLI, a small molecule MEK inhibitor, for the treatment of adult and pediatric patients 2 years ...

BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat neurofibromatosis type 1 (NF1), a rare genetic disorder affecting approximately 100,000 ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Apellis Pharmaceuticals (APLS – Research ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

This article summarizes the most significant insider buying and selling activities reported for Wednesday, February 12, 2025, ...

As the demand for novel therapies and personalized medicine surges, leaders are uniquely positioned to create a culture of creativity, collaboration and innovation.